|
|
|
| Evaluation on Therapeutic Efficacy of Chuankezhi by Different Administration Pathways Combined with Salmeterol Rinafoate and Fluticasone Propionate Powder for Inhalation on Acute Exacerbation of Moderate-Severe COPD |
| LI Meng, HUANG Minqiang, HE Guanghui, et al |
| Nanxiang Hospital of Shanghai Jiading District, Shanghai Jiading District 201802, China |
|
|
|
|
Abstract Objective: To investigate therapeutic efficacy evaluation of chuankezhi injection by different administration pathways combined with salmeterol xinafoate and fluticasone propionate powder for inhalation in the treatment of acute exacerbation of moderate-severe chronic obstructive pulmonary disease (COPD). Methods: 90 cases of moderate-severe COPD in acute exacerbation treated in our hospital from January 2016 to April 2018 were selected and equally divided into two groups. The control group received the salmeterol xinafoate and fluticasone propionate powder for inhalation, while the treatment group received the chuankezhi by different administration combined with salmeterol xinafoate and fluticasone propionate powder for inhalation. Then the clinical efficacy, adverse reactions, pulmonary function indicators, blood gas parameters, mMRC scores, and CAT scores of the two groups were compared. Results: The total clinical efficacy of the treatment group was higher than that of the control group, and the difference was statistically significant (88.89% vs 71.11%, P<0.05); The FEV1, FEV1/FVC, PEF and 6min walking distance of the two groups were increased after treatment, and were higher in the treatment group than those in the control group (P<0.05); The PaCO2 of the two groups were decreased, while the PaO2 and SaO2 were increased after treatment (P<0.05); The treatment group had lower level of PaCO2 as well as higher levels of PaO2 and SaO2 than those of the control group (P<0.05); The scores of mMRC and CAT of the two groups were decreased (P<0.05), and were lower in the treatment group than in the control group (P<0.05); The incidence rate of the adverse reactions of the two groups had no difference (8.88% vs 6.66%, P>0.05). Conclusion: Chuankezhi injection by different administration pathways combined with salmeterol xinafoate and fluticasone propionate powder for inhalation is an effective way to ameliorate the pulmonary function, blood indexes and quality of life for acute exacerbation of moderate-severe COPD.
|
|
|
|
|
|
[1] 蔡柏蔷.慢性阻塞性肺疾病诊断、处理和预防全球策略(2017GOLD报告)解读[J].国际呼吸杂志,2017,37(1):6~17.
[2] 曹凤华,赵琳.舒利迭联合噻托溴胺吸入治疗稳定期中重度慢性阻塞性肺疾病的疗效观察[J].宁夏医科大学学报,2015,37(6):704~706.
[3] 赵洪.噻托溴铵联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的疗效及安全性[J].安徽医药,2015,18(8):1593~1595.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255~264.
[5] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.163~167.
[6] 刘欣欣,王浩彦,张曼林,等.改良版英国医学研究会呼吸困难量表评分及肺功能测定对慢性阻塞性肺疾病患者运动能力的预测价值研究[J].临床内科杂志,2016,33(6):404~406.
[7] 柳涛,蔡柏蔷.一种新型的生活质量评估问卷:慢性阻塞性肺疾病评估测试[J].中国医学科学院学报,2010,32(2):234~238.
[8] 谈飒英,倪伟,吴淑红.咳喘六味合剂联合小剂量舒利迭治疗慢性阻塞性肺疾病临床疗效观察[J].四川中医,2017,35(6):84~85.
[9] 田亚莉.舒利迭联合BiPAP通气治疗稳定期重度COPD 80例疗效及安全性分析[J].检验医学与临床,2015,15(7):984~985.
[10] 王嵘,和晓华,杨眉.舒利迭联合布地奈德治疗老年患者重度哮喘急性发作的临床研究[J].实用老年医学,2015,29(1):52~54.
[11] 江容飞,徐玲,李小华.肺康复训练联合吸入舒利迭与噻托溴铵对中重度COPD患者肺功能、运动耐力及生活质量的影响[J].实用临床医药杂志,2017,21(9):28~30.
[12] 韩辉.舒利迭联合思力华治疗对稳定期慢性阻塞性肺疾病患者的疗效及肺功能的影响[J].实用临床医药杂志,2016,20(3):135~136.
[13] Malekiyazdi M R, Kelly S M, Lam S Y, et al. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada.[J]. Canadian Respiratory Journal of the Canadian Thoracic Society,2016,19(5):319~320.
[14] 朱越燕,张孝钦,薛骞.喘可治雾化治疗COPD急性发作期疗效观察[J].中药材,2015,38(4):875~877.
[15] 张一乐,史苗颜,张炜.喘可治注射液不同给药方式治疗稳定期COPD患者的疗效比较研究[J].上海中医药杂志,2016,61(7):40~43. |
|
|
|
2019, Vol. 25 
